Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company dedicated to developing innovative therapies for hard-to-treat tumors and viruses. The company's lead candidate, Annamycin, is advancing in the pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML), with the first unblinding of data anticipated in Q1 2026.
Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, built around its proprietary POZ Platform, a drug optimization technology based on a controlled, water-soluble poly(2-oxazoline) polymer. The platform is designed to tune half-life, exposure and tissue distribution of small molecules, peptides and biologics, with the ambition of generating “best-in-class” dosing profiles versus conventional formulations.
The FSGS decision remains a high-impact regulatory binary. The piece focuses on the run-up logic but does not remove the fundamental FDA risk from the picture.
FDA asks for the full HOPE-3 clinical study report but does not require new trials, while Capricor prepares a February BLA update. The stock hovers around 23–24 $, with a market cap near 1.16 B$, after a 2025 rally fuelled by Duchenne data and aggressive retail positioning.
FDA places a clinical hold on RGX-111 (MPS I) and RGX-121 (MPS II) programs after a single intraventricular CNS tumor in an RGX-111 patient.
Preliminary analysis shows an AAV vector integration event near proto-oncogene PLAG1; causality is still under investigation.
NAVSUNLI (RGX-121) BLA for MPS II remains under priority review with a PDUFA date of February 8, 2026; no public change to that date has been announced as of this report.
Ondas Inc. (NASDAQ: ONDS) announced that the Optimus drone from its American Robotics unit has been added to the DCMA “Blue List” of approved unmanned aircraft systems. This confirms compliance with Department of War cybersecurity, supply chain and operational standards and opens a faster lane for U.S. government and defense procurement of Optimus.
At Merlintrader we’ve been following Ondas for a while through this steep progression, and today’s move is another step in the transition from a niche wireless/IoT story towards a more clearly defined dual-use autonomous infrastructure profile.
Today’s move is all about a fresh U.S. Air Force Research Laboratory contract: the headline is “swarming,” but the real keyword is integration—getting drones, ships, ground systems, and now satellites to share ISR and coordinate as one network. Below: what happened, what it could mean, what can still go wrong, and the key numbers double-checked from SEC filings and official releases.
Rocket Lab is one of the few listed names sitting at the intersection of launch services, space infrastructure and US national security. In the last weeks, three threads have converged: a record defence contract for missile-tracking satellites, a visible test failure on the new Neutron rocket, and a high-visibility hardware milestone with the arrival of the “Hungry Hippo” fairing at the Virginia launch complex.
As of January 27, 2026, Cardiff Oncology (NASDAQ: CRDF) is trading around 2 dollars per share after a single-session loss of roughly thirty-two percent. The trigger was a GlobeNewswire press release announcing that long-time Chief Executive Officer Mark Erlander and Chief Financial Officer James Levine are both stepping down, with board member Mani Mohindru becoming interim CEO and Senior Vice President of Finance Brigitte Lindsay moving up as interim CFO.
As of January 27, 2026, Intellia Therapeutics (NASDAQ: NTLA) is back in the spotlight. The FDA has lifted the clinical hold on MAGNITUDE-2, the Phase 3 study of its in vivo CRISPR therapy nexiguran ziclumeran (“nex-z”, formerly NTLA-2001) in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), while a separate large cardiomyopathy trial (MAGNITUDE, ATTR-CM) remains on hold after a Grade 4 liver event and a subsequent patient death triggered intense scrutiny.
COYA Therapeutics Holdings represents a high-risk opportunity in the biotech sector, focused on developing innovative therapies for neurodegenerative and autoimmune diseases through regulatory T-cell (Treg) modulation. With a pipeline including candidates for ALS, Alzheimer's, and other complex pathologies, the company positions itself in a therapeutic area with significant unmet medical needs but also with high clinical failure rates.
Kura Oncology is a precision oncology company built around one central thesis: targeting oncogenic signalling nodes such as menin and farnesyl transferase can reset the biology of hard-to-treat cancers, especially acute myeloid leukemia (AML).
Redwire is moving from niche space supplier to integrated space-and-defense player just as the Golden Dome and SHIELD architectures turn from political slogan into multi-decade procurement programs. The stock has already rerated on expectations; the question now is whether cash flow, backlog and contract wins will catch up with the narrative.
aTyr Pharma ($ATYR) is a clinical-stage biotech developing first-in-class therapies from its tRNA synthetase platform, targeting fibrotic and inflammatory lung diseases. The company's lead asset, efzofitimod (a selective NRP2 modulator), suffered a major setback with the Phase 3 EFZO-FIT trial miss in pulmonary sarcoidosis (announced Sept 15, 2025), causing an ~80% stock drop from ~$4-5 to sub-$1 levels.
Vanda is not a pre-revenue biotech: it is a commercial-stage CNS company with three marketed products (Fanapt, Hetlioz, Ponvory) and two late stage assets that matter for the next 12–24 months: Nereus (tradipitant) for motion sickness, now approved, and Bysanti (milsaperidone) with a PDUFA target action date on 21 February 2026 for schizophrenia and bipolar I disorder.
Viridian Therapeutics (VRDN) has started 2026 by reaffirming its "transformational" year narrative in the January 6 PR, which serves as a comprehensive roadmap update without any timeline shifts or negative surprises. This builds directly on the December 22, 2025 BLA acceptance for veligrotug (VRDN-001) in TED with Priority Review and PDUFA target of June 30, 2026 (as detailed in the previous report).
Latest verified update · July 22, 2026 Celcuity is now a commercial-stage oncology launch story after REVTORPYK approval Celcuity crossed a major threshold on July 14, 2026 with FDA approval of REVTORPYK™ / gedatolisib for HR-positive, HER2-negative, PIK3CA wild-type advanced…
RGX-121 puts Regenxbio at the threshold of its first potential standalone approval, while the retina (AbbVie) and Duchenne programs build a second and third pillar for 2026–2027. The equity story is a classic “platform + royalty + binary PDUFA” mix, with a balance sheet extended into early 2027 via upfronts and royalty monetization.
Cadrenal Therapeutics (NASDAQ: CVKD) is a clinical-stage biopharma headquartered in Ponte Vedra, Florida, focused on anticoagulation solutions for high-risk patients who are poorly served by current therapies. The company was formed in 2022 around tecarfarin and, through two 2025 acquisitions, has expanded into a broader platform combining VKA, Factor XIa and 12-LOX mechanisms.
Going into the 27–28 January FOMC, the message is basically “don’t expect fireworks”: after the 2025 cuts, the Fed keeps describing policy as “well positioned”, with inflation gliding down towards (but not yet at) target and real growth still positive. Futures now see a very high probability of a clean hold next week and push the bulk of any extra easing into late 2026.